XML 32 R21.htm IDEA: XBRL DOCUMENT v3.5.0.1
Background, Basis of Presentation, Economic Dependency and Significant Accounting Policies: - Basis of Presentation thru Fair Value of Financial Instruments (Details)
12 Months Ended
Feb. 29, 2016
USD ($)
item
shares
Feb. 28, 2015
USD ($)
shares
Background, Basis of Presentation, Economic Dependency and Significant Accounting Policies:    
Percentage of outstanding stock owned by the President and Chairman of the Board 81.00%  
Number of antineoplaston drugs that have received FDA approval | item 0  
Economic Dependency    
Significant external revenue $ 0 $ 0
Working capital deficit 102,000  
Accumulated deficit 117,268,812 115,263,712
Losses incurred $ 2,005,100 2,892,048
Estimated percentage of Dr. Burzynski's patients admitted and treated as part of clinical trial programs 10.00%  
Income Taxes    
Uncertain tax positions $ 0 $ 0
Loss Per Common Share    
Warrants and stock options excluded from calculation of diluted loss per share (in shares) | shares 1,600,000 1,600,000
Fair Value of Financial Instruments    
Number of financial instruments held for trading purposes | item 0  
Minimum    
Property and Equipment    
Estimated useful lives 5 years  
Maximum    
Property and Equipment    
Estimated useful lives 10 years